Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioDFence G3 Placental Tissue Membrane is a dehydrated, multilayer human amnion and chorion allograft (dHACM) derived from human placental tissue. Developed and distributed by Integra LifeSciences, it is designed to serve as a resorbable surgical barrier and wrap that preserves tissue planes and reduces the formation of scar tissue. The membrane acts as a bioactive scaffold that supports the natural healing cascade and prevents fibroblast infiltration between adjacent tissues. It is primarily investigated for use during robotic-assisted radical prostatectomy, where it is wrapped around neurovascular bundles to promote the early recovery of erectile function and urinary continence. As a human tissue-based product, it is regulated by the FDA under the HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products) framework.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BioDFence G3 Placental Tissue Membrane.